rDEN2delta30-7169 for Dengue Fever

This trial aims to learn more about dengue fever, a mosquito-borne virus that can cause severe symptoms like shock and internal bleeding. Researchers will use a weakened version of the dengue virus, called rDEN2delta30-7169, to observe how healthy individuals' bodies react. Participants should be in good health and may or may not have been exposed to dengue previously. The study involves multiple visits over six months, during which participants will undergo blood tests and other exams to monitor their response. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot take potent anticoagulants like warfarin during the first 28 days. If you're on other medications, it's best to discuss with the study staff.

Studies have shown that the rDEN2delta30-7169 treatment, a weakened form of the dengue virus, is undergoing safety testing. Research indicates that this modified virus is designed to be less harmful than the natural virus. The study primarily aims to assess its safety and how individuals, especially those with varying histories of dengue virus exposure, respond to it.

Unlike the standard of care for dengue fever, which often includes supportive treatments like fluids and pain relievers, rDEN2delta30-7169 is a vaccine candidate specifically targeting the dengue virus. Researchers are excited about this treatment because it introduces a modified live attenuated virus designed to provoke a strong immune response without causing disease. This vaccine is tailored for different groups based on their exposure to flaviviruses, potentially offering a more personalized and effective approach to preventing dengue infections.

Research has shown that rDEN2delta30-7169 is being explored as a potential treatment for dengue by using a weakened form of the virus. This method aims to safely activate the body's immune system to combat the virus. Previous studies demonstrated that a weakened virus can help the immune system learn to recognize and fight the stronger version of the virus. Although direct evidence of its effectiveness against dengue is not yet available, this strategy resembles vaccines that have succeeded in treating other diseases. Early signs suggest it could aid in understanding and managing dengue infections. Participants in this trial will be divided into groups based on their previous exposure to flaviviruses, with arms labeled as Naive, Heterotypic, and Homotypic, to assess the treatment's effectiveness across different immune backgrounds.⁶⁷⁸⁹¹⁰